To read the full story, subscribe or sign in.

Elpiscience acquires China rights for dual angiogenic bispecific antibody from Trigr Therapeutics

Jan. 26, 2021

HONG KONG – Irvine, Calif.-based Trigr Therapeutics Inc. has signed an exclusive licensing deal with Shanghai-based Elpiscience Biopharmaceuticals Co. Ltd., known as Kewang in China. The two companies will develop and commercialize TR-009 in mainland China, Hong Kong, Macau and Taiwan.

BioWorld BioWorld Asia Deals and M&A License

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for March 5.

Gloved hand places sample tubes in PCR system

COVID-19 test makers are adapting for variants

BioWorld MedTech

As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for March 5.

Coronavirus vaccine/therapeutics illustration

Tonix looks to the past for the future of COVID-19 vaccines and testing

BioWorld MedTech

Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...